LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Home・Aandelen Lijst・Cogent Biosciences Inc

Cogent Biosciences Inc

Gesloten

39.63 0.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

39.54

Max

40.16

Belangrijke statistieken
By Trading Economics
Inkomsten	-7.4M -81M
EPS	-0.5
Winstmarge	-1,582.642
Werknemers	205
EBITDA	-6.8M -79M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+17.55% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.9B 6B
Vorige openingsprijs	39.55
Vorige sluitingsprijs	39.63

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

4.88 / 5.87 Steun & Weerstand

Cogent Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 dec 2025, 14:57 UTC

Acquisities, Fusies, Overnames

Accenture to Acquire Cabel Industry from Fibonacci Group

25 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec 2025, 00:20 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 dec 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

24 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 dec 2025, 17:08 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 16:53 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 dec 2025, 16:31 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 dec 2025, 16:28 UTC

Acquisities, Fusies, Overnames

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 dec 2025, 16:17 UTC

Marktinformatie

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 dec 2025, 15:33 UTC

Acquisities, Fusies, Overnames

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 dec 2025, 15:30 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 15:19 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:49 UTC

Acquisities, Fusies, Overnames

Mexico's Ollamani Sells Stake in Azteca Stadium

24 dec 2025, 14:19 UTC

Marktinformatie

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 dec 2025, 14:08 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 dec 2025, 14:06 UTC

Marktinformatie

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 dec 2025, 13:24 UTC

Marktinformatie

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 dec 2025, 12:59 UTC

Acquisities, Fusies, Overnames

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 dec 2025, 12:51 UTC

Acquisities, Fusies, Overnames

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Peer Vergelijking

Prijswijziging

Cogent Biosciences Inc Prognose

Koersdoel

By TipRanks

17.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 47.22 USD 17.55%

Hoogste 67 USD

Laagste 34 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cogent Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Cogent Biosciences Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

4.88 / 5.87Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.